We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Pot-Kast: Thrombosis Prophylaxis After Knee Arthroscopy (Pot-Kast)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01542723
Recruitment Status : Completed
First Posted : March 2, 2012
Last Update Posted : October 11, 2016
ZonMw: The Netherlands Organisation for Health Research and Development
Information provided by (Responsible Party):
Suzanne C. Cannegieter, MD PhD, Leiden University

Brief Summary:

Currently, guidelines and clinical practice differ considerably with respect to use of anticoagulant treatment after arthroscopy of the knee. Trials that have been carried out were aimed at efficacy only, had small sample sizes and therefore mainly used asymptomatic thrombosis as endpoint. From these trials an overall risk benefit-balance could not be established, hence the current controversy. In the proposed study the investigators will use relevant symptomatic endpoints in a large cohort of patients. Furthermore the investigators will follow subjects with an adverse event for a longer period, during which the investigators will assess the long term sequelae of these events. Lastly, the investigators will determine high risk groups that will benefit most from anticoagulant treatment.

Objective: Comparative effectiveness research to determine cost-effectiveness of two existing policies, i.e. treatment with low molecular weight heparin (LMWH) after arthroscopy of the knee. In addition the investigators will investigate personalized prophylaxis based on genetic and acquired risk factors.

Condition or disease Intervention/treatment
Deep Venous Thrombosis Pulmonary Embolism Drug: LMWH

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1500 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Pot-Kast: Thrombosis Prophylaxis After Knee Arthroscopy: Determining the Balance Between Benefits and Risks
Study Start Date : May 2012
Primary Completion Date : July 2016
Study Completion Date : September 2016

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: LMWH
750 patients with an arthroscopy or the knee will be randomized to receive treatment with a LMWH
Drug: LMWH

Each hospital will use a LMWH according to their own preferences.

Prophylactic dosage of LMWH (for example nadroparin 2850 IE s.c.) once daily for 8 days. If the patient's weight is more than 100kg a double dose of LMWH will be given (in case of Nadroparin 5700 IE s.c. once daily).

Other Names:
  • Nadroparine
  • Dalteparine
No Intervention: No intervention
750 patients with an arthroscopy of the knee will be randomized to receive no treatment.

Primary Outcome Measures :
  1. Symptomatic deep venous thrombosis (DVT) [ Time Frame: 3 Months ]
    Symptomatic deep venous thrombosis confirmed with compression ultrasonography

  2. Pulmonary Embolism (PE) [ Time Frame: 3 months ]

    Fatal or non-fatal pulmonary embolism confirmed with:

    • an intraluminal filling defect in segmental or more proximal branches on spiral CT scan, or
    • a perfusion defect of at least 75% of a segment with a local normal ventilation result (high-probability) on ventilation/perfusion lung scan, or
    • detected at autopsy

  3. Major Bleeding [ Time Frame: 3 months ]

    Major bleeding, defined as:

    • a fatal bleeding, or
    • symptomatic bleeding in a critical area or organ, or
    • extrasurgical site bleeding causing a fall in hemoglobin level of 1.24mmol/L (2.0g/dL) or more, leading to transfusion of one or more units of whole blood or red cells, or
    • surgical site bleeding that requires a second intervention or a hemarthrosis interfering with rehabilitation, or surgical site bleeding that needs blood suppletion.

Secondary Outcome Measures :
  1. Other clinically relevant bleeding [ Time Frame: 3 months ]
    Other clinically relevant bleeding, defined as overt bleeding not meeting the criteria for major bleeding but associated with medical intervention, unscheduled contact with a physician, (temporary) cessation of study treatment, or associated with discomfort such as pain, or impairment of activities of daily life.

  2. Surgical site infection [ Time Frame: 3 months ]
    Superficial incisional surgical site infection, deep incisional surgical site infection of organ/space surgical site infection according to the definitions of the CDC.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Meniscectomy
  • Diagnostic Arthroscopy
  • Removal of corpora libera

Exclusion Criteria:

  • Contra-indications for LMWH use (recent major bleeding, bleeding disorder, allergy)
  • Pregnancy
  • Pre-existent indication for anticoagulation therapy, either LMWH or vitamin K antagonists.
  • History of venous thromboembolism (indication for anticoagulation therapy for prophylaxis of recurrence)
  • Mental of physical disability to fulfill study requirements
  • Insufficient knowledge of the Dutch language
  • Previous participation in the Pot-(K)Cast study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01542723

Isala Klinieken
Zwolle, Overijsel, Netherlands, 8011 JW
Alrijne Ziekenhuis
Leiderdorp, Zuid Holland, Netherlands, 2353 GA
Delft, Zuid-Holland, Netherlands, 2616 LS
Reinier de Graaf Groep
Delft, Zuid-Holland, Netherlands, 2625 AD
Medisch Centrum Haaglanden
Den Haag, Zuid-Holland, Netherlands, 2512 VA
Den Haag, Zuid-Holland, Netherlands, 2566 MJ
Groene Hart Ziekenhuis
Gouda, Zuid-Holland, Netherlands, 2803 HH
Leiden University Medical Center
Leiden, Zuid-Holland, Netherlands, 2333 ZA
Rotterdam, Zuid-Holland, Netherlands, 3067 GH
Sponsors and Collaborators
Suzanne C. Cannegieter, MD PhD
ZonMw: The Netherlands Organisation for Health Research and Development
Study Director: Suzanne C Cannegieter, PhD, MD Leiden University Medical Center
Principal Investigator: Rob GHH Nelissen, PhD, MD Leiden University Medical Center

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Suzanne C. Cannegieter, MD PhD, Study director, Leiden University
ClinicalTrials.gov Identifier: NCT01542723     History of Changes
Other Study ID Numbers: NL35774.058.11(2)
First Posted: March 2, 2012    Key Record Dates
Last Update Posted: October 11, 2016
Last Verified: October 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Keywords provided by Suzanne C. Cannegieter, MD PhD, Leiden University:
Deep venous thrombosis
Pulmonary Embolism
Arthroscopy of the knee

Additional relevant MeSH terms:
Pulmonary Embolism
Venous Thrombosis
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action